Amundi
PTGX icon

Amundi’s Protagonist Therapeutics PTGX Stock Holding History

Amundi’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$943K Buy
7,692
+3,579
+87% +$374K ﹤0.01% 1399
2026
Q1 		$434K Buy
+4,113
New +$364K ﹤0.01% 1602
2025
Q2 		– Sell
-2,058
Closed -$95.7K – 2060
2025
Q1 		$95.7K Buy
2,058
+25
+1% +$1.05K ﹤0.01% 1753
2024
Q4 		$76.5K Hold
2,033
– – ﹤0.01% 1816
2024
Q3 		$89.4K Sell
2,033
-674
-25% -$27.2K ﹤0.01% 1789
2024
Q2 		$93.4K Hold
2,707
– – ﹤0.01% 1717
2024
Q1 		$68.3K Buy
2,707
+675
+33% +$18.4K ﹤0.01% 1815
2023
Q4 		$51.6K Sell
2,032
-1,687
-45% -$29.5K ﹤0.01% 1885
2023
Q3 		$57.4K Hold
3,719
– – ﹤0.01% 1850
2023
Q2 		$83K Buy
+3,719
New +$93.1K ﹤0.01% 1807
2022
Q2 		– Sell
-3,855
Closed -$98K – 1704
2022
Q1 		$98K Sell
3,855
-198
-5% -$5.58K ﹤0.01% 1474
2021
Q4 		$141K Buy
+4,053
New +$128K ﹤0.01% 1528

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Amundi's PTGX Position: Q2 2026 in Review

Amundi increased its Protagonist Therapeutics (PTGX) stake by 87% in Q2 2026, buying an estimated $374K and bringing the position to 7,692 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #1399.

Amundi first reported a position in PTGX in Q4 2021 and has held it in 12 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Amundi held 7,692 shares of Protagonist Therapeutics worth $943K as of Q2 2026.
  • Amundi bought 3,579 Protagonist Therapeutics shares in Q2 2026, an estimated $374K.
  • Protagonist Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1399 holding.
  • Amundi first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.